Bass Pfishing and Hedge Fund Hijinks
Hedge-fund investors are coming to raid your medicine cabinet. Cutting-edge treatments for diseases affecting millions of Americans are threatened by Wall Street’s latest moneymaking scheme. The ploy: Hedge funds bet against a drug company’s stock price, launch attacks against the firm’s patents on its best-selling medicines and then reap windfall profits when investors panic and the stock price plummets. Unless Congress protects pharmaceutical-research firms from these assaults, funding for drug discovery will dry up and many new treatments won’t ever make it into the hands of patients. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 23, 2015 Category: Pharmaceuticals Source Type: blogs
Turkish Delight
I’ve just returned from the World Cancer Leaders’ Summit in Istanbul. (The event was held in partnership with the International Agency for Research on Cancer, the International Atomic Energy Agency (IAEA), and the World Health Organization.) It was a Turkish delight in more ways than one. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 19, 2015 Category: Pharmaceuticals Source Type: blogs
The Truth About Specialty Drugs
The truth about the real cost and value of new medicines is revealed in this important essay (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 10, 2015 Category: Pharmaceuticals Source Type: blogs
Kansas City Royals Fans Have Another Reason To Celebrate
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - November 2, 2015 Category: Pharmaceuticals Source Type: blogs
BioPharm companies are Inviting Price Controls By Inaction
Stuffing victory down the jaws of defeat (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 29, 2015 Category: Pharmaceuticals Source Type: blogs
Don Wright: Outrunning Cancer
(Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 23, 2015 Category: Pharmaceuticals Source Type: blogs
Towards an Intramural Approach to Biomarkers
FDA can further solidify its place squarely in the center of the innovation ecosystem by fostering collaborative alliances with all stakeholders, enhancing qualification planning, sharing developmental endeavors, and clarifying standards. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 21, 2015 Category: Pharmaceuticals Source Type: blogs
Insurers Rack Up Profits Raising Consumer Drug Costs
Insurers and PBMs are forcing consumers to pay more for medicines that save's everyone money. How fair is that? (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 20, 2015 Category: Pharmaceuticals Source Type: blogs
Price Controls Restrict The RIght To Live
Price controls will make living less affordable and assisted suicide a more viable option (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 15, 2015 Category: Pharmaceuticals Source Type: blogs
CDC and Opioids. Conflict? What Conflict?
On every count the CDC fails the test of intellectual conflict of interest. According to the CDC, they agency “aimed to minimize conflict of interest, enhance objective assessment of the evidence, and reduce bias.” Well, they may have aimed – but they missed badly. The members of this group do not represent a broad spectrum of thought on opioids. To put it nicely, the issue of normative bias needs to discussed –loudly and openly. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 14, 2015 Category: Pharmaceuticals Source Type: blogs
Mountain Due
When it comes to the price/value debate, the truth, as Oscar Wilde so aptly put it, is rarely pure and never simple. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 9, 2015 Category: Pharmaceuticals Source Type: blogs
CDC's Flawed Opioid Efforts. Attention must be paid.
When it comes to the CDC’s new opioid guidelines, attention must be paid -- immediately and publicly. This is the message from a growing constituency of physicians, patients and policy experts concerned and upset about both the CDC’s conflict-ridden, secretive process and, even more importantly, the guidelines themselves. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - October 8, 2015 Category: Pharmaceuticals Source Type: blogs
Opioids and Sunshine at the CDC
When a federal agency tries to hide what should be an open and transparent process, sunshine has a way of breaking though the curtains. Here for the first time (and from inside the belly of the beast) is the CDC’s confidential document, “CDC Guideline for Prescribing Opioids for Chronic Pain.” It includes a complete list of the Core Expert Group. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - September 24, 2015 Category: Pharmaceuticals Source Type: blogs
Cry 'Hemorrhoids!', and let slip the dogs of war
What do the Caronia, Vascepa, and Pacria cases have in common? Well, for one thing all the plaintiffs are small companies, largely dependent on the sales of a single product for their revenues. Suing the FDA used to be considered a high-stakes gamble, but recent rulings – and the lack of action on the part of the agency to put forward new draft guidance – seem to have changed the risk/benefit analysis. At least for small companies. (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - September 10, 2015 Category: Pharmaceuticals Source Type: blogs
Biosimilar Prices Bode Well For Innovation
Can we say authorized generic? (Source: drugwonks.com Blog)
Source: drugwonks.com Blog - September 3, 2015 Category: Pharmaceuticals Source Type: blogs
